{"filing":{"accession_number":"0001714899-26-000086","cik":"0001714899","ticker":"DNLI","company_name":"Denali Therapeutics Inc.","form":"8-K","filing_date":"2026-07-27","report_date":"2026-07-27","primary_document":"dnli-20260727.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/dnli-20260727.htm"},"events":[{"id":20826,"run_id":18744,"accession_number":"0001714899-26-000086","anchor_item_number":"2.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The disclosure describes completion of a sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $195.0 million gross proceeds. While this is an asset disposition, it is not a material acquisition, merger, or change of control (which would trigger `ma_activity`). The PRV is a regulatory asset with significant financial value, making this a material financial event that does not fit the specific `ma_activity` category; `financial_other` is the appropriate classification for a material asset sale that falls outside the M\u0026A scope.","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20305,"accession_number":"0001714899-26-000086","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes completion of a sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $195.0 million gross proceeds. While this is an asset disposition, it is not a material acquisition, merger, or change of control (which would trigger `ma_activity`). The PRV is a regulatory asset with significant financial value, making this a material financial event that does not fit the specific `ma_activity` category; `financial_other` is the appropriate classification for a material asset sale that falls outside the M\u0026A scope.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:06:48.989285+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20305,"accession_number":"0001714899-26-000086","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes completion of a sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $195.0 million gross proceeds. While this is an asset disposition, it is not a material acquisition, merger, or change of control (which would trigger `ma_activity`). The PRV is a regulatory asset with significant financial value, making this a material financial event that does not fit the specific `ma_activity` category; `financial_other` is the appropriate classification for a material asset sale that falls outside the M\u0026A scope.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:06:48.989285+00:00","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-07-27"}]}